Dynamic Healthcare M&A Database

Acquiring Party	Johnson & Johnson (JNJ), a $61.4b pharmaceutical and medical device manufacturer.
Transferring Party	Elan Corporation, an Irish biotech corporation.
Sector	Biopharmaceuticals
Date	July 3, 2009
Analysis J&J enters the high-stakes race to find new medicines for Alzheimer's disease by paying $1.5b for a 18.5% stake in Elan, which has had a 10-year collaboration with Wyeth to find a drug to address the build-up of amyloid plaques in the brain, one of the trademarks of Alzheimers. The program includes a prospective vaccine for Alzheimer's. As part of the deal J&J will create a separate company and commit up to $500m to continue the development of bapineuzumab. Elan receives a 49.9% interest in the new J&J company. By 2015, Alzheimer's could afflict as many as 6.5 million Americans; industry analysts predict a new disease-modifying medicine could generate as much as $10b in annual sales.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 3Q09